Abstract
Background: CNS metastases in patients with ALK-positive NSCLC are a cause of substantial morbidity and mortality. Alectinib had demonstrated promising intracranial efficacy in several prospective clinical trials. But there was limited data on intracranial response of Alectinib in real world setting.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
